Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia

Overview of attention for article published in Journal of Cancer Research and Clinical Oncology, April 2019

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (59th percentile)
Good Attention Score compared to outputs of the same age and source (65th percentile)

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 17 Dimensions

Readers on

mendeley: 39 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 3,300 followers.

RT @jvalentingg: Newly diagnosed patients with CP CML receiving bosutinib or imatinib can preserve or improve HRQoL. Proud to be part of th…

18 Apr 2019

Reply Repost Favourite

RT @jvalentingg: Newly diagnosed patients with CP CML receiving bosutinib or imatinib can preserve or improve HRQoL. Proud to be part of th…

18 Apr 2019

Reply Repost Favourite

RT @jvalentingg: Newly diagnosed patients with CP CML receiving bosutinib or imatinib can preserve or improve HRQoL. Proud to be part of th…

18 Apr 2019

Reply Repost Favourite

Newly diagnosed patients with CP CML receiving bosutinib or imatinib can preserve or improve HRQoL. Proud to be part of this trial. https://t.co/CJDcW70LMP

18 Apr 2019

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.